VYNE
Vyne Therapeutics Inc
NASDAQ · Pharmaceuticals
$0.56
+0.00 (+0.48%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.79M | 2.72M | 3.05M |
| Net Income | 589.8K | 604.8K | 522.0K |
| EPS | — | — | — |
| Profit Margin | 21.2% | 22.3% | 17.1% |
| Rev Growth | +10.4% | -5.6% | +23.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 6.83M | 5.81M | 7.24M |
| Total Equity | 10.41M | 10.77M | 11.64M |
| D/E Ratio | 0.66 | 0.54 | 0.62 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 828.7K | 831.2K | 1.01M |
| Free Cash Flow | 400.3K | 485.0K | 536.6K |